Constellation Pharmaceuticals, Inc. Appoints Mark A. Goldsmith, M.D., Ph.D. as CEO and Closes $17 Million in Funding.
Business Wire › August 13, 2009
Linked as:
Extract
Constellation Pharmaceuticals, Inc. Appoints Mark A. Goldsmith, M.D., Ph.D. as CEO and Closes $17 Million in Funding.
Company Leading Emerging Field of Epigenetics
CAMBRIDGE, Mass. -- Constellation Pharmaceuticals, Inc., the leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced that it has appointed Mark A. Golds...See the full content of this document
Sponsored links
